SCHEMBL5459124

SCHEMBL5459124

COc1ccc(C(N)c2ccc(C(=O)Nc3ccncc3)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 2/20 0.67
ROCK1 Q13464 2/20 0.67
RAB9A P51151 6/20 0.62
NPC1 O15118 4/20 0.62
KMT2A Q03164 4/20 0.62
MEN1 O00255 3/20 0.62
POLB P06746 2/20 0.62
TP53 P04637 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
ALOX15 P16050 1/20 0.61
NAMPT P43490 1/20 0.58
PSMD14 O00487 1/20 0.58
KDM4E B2RXH2 2/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
LMNA P02545 4/20 0.58
BCHE P06276 1/20 0.57
ACHE P22303 1/20 0.57
ALDH1A1 P00352 2/20 0.56
MAPK1 P28482 1/20 0.56
STAT3 P40763 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3270932 0.89 RAB9A (0.77) RAB9ANPC1KMT2AMEN1POLB
SCHEMBL3504765 0.88 ROCK2 (0.61) ROCK2ROCK1RAB9ANPC1KMT2A
SCHEMBL2790882 0.86 ROCK2 (0.58) ROCK2ROCK1RAB9ANPC1KMT2A
SCHEMBL2793073 0.86 ROCK2 (0.62) ROCK2ROCK1RAB9ANPC1KMT2A
SCHEMBL20284424 0.85 RAB9A (0.71) RAB9ANPC1KMT2AMEN1POLB
SCHEMBL5456383 0.85 KMT2A (0.72) RAB9ANPC1KMT2AMEN1POLB
SCHEMBL5466401 0.83 ROCK2 (0.69) ROCK2ROCK1RAB9ANPC1KMT2A
SCHEMBL3271513 0.83 RAB9A (0.77) RAB9ANPC1KMT2AMEN1POLB
SCHEMBL2792198 0.83 ROCK2 (0.55) ROCK2ROCK1RAB9ANPC1KMT2A
SCHEMBL2796251 0.83 NAMPT (0.66) ROCK2ROCK1RAB9ANPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191420-A1 Kinase inhibitors DEVGEN NV 2007-08-16 US claimed
EP-1715862-A1 KINASE INHIBITORS Devgen NV (BE) 2006-11-02 EP claimed
WO-2005082367-A1 KINASE INHIBITORS DEVGEN NV (BE) 2005-09-09 WO claimed
US-20070191420-A1 Kinase inhibitors DEVGEN NV 2007-08-16 US disclosed
US-20070191420-A1 Kinase inhibitors DEVGEN NV 2007-08-16 US disclosed
US-20070191420-A1 Kinase inhibitors DEVGEN NV 2007-08-16 US disclosed
EP-1715862-A1 KINASE INHIBITORS Devgen NV (BE) 2006-11-02 EP disclosed
WO-2005082367-A1 KINASE INHIBITORS DEVGEN NV (BE) 2005-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191420-A1 Kinase inhibitors ROCK1, ROCK2, MAP3K20 ROCK2 2/4885ROCK1 1/4885RAB9A 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.